SABRA MAZIN 4

What Happened

• Sabra Mazin, Chief Operating Officer of ClearPoint Neuro, had 13,827 restricted stock units (RSUs) convert into common shares on March 6, 2026 (reported on a Form 4 filed March 10, 2026). As part of the vesting settlement, 7,036 shares were delivered back to the company to satisfy tax withholding obligations at a reported value of $10.00 per share (total withheld = $70,360).
• This transaction is a scheduled RSU vesting/settlement (not an open-market buy or sale). The withholding of shares to cover taxes is a common, routine administrative step rather than a directional market trade.

Key Details

• Transaction date: March 6, 2026; Form 4 filed: March 10, 2026 (timely within SEC filing window).
• Primary actions reported: Conversion/exercise of derivative (RSU settlement) for 13,827 shares; 7,036 shares withheld to cover tax liability at $10.00/share (withheld value $70,360).
• Shares owned after transaction: Not specified in the Form 4.
• Footnotes: F1 — these were RSUs settled on their scheduled vesting date; F2 — the 7,036 shares were surrendered to satisfy tax withholding.
• Filing timeliness: Filed within the required period (not marked late).

Context

• For retail investors: RSU settlements are compensation vesting events and are routine for executives; the withholding of shares to cover taxes is effectively a cashless surrender and does not necessarily indicate buying or selling sentiment.
• Transaction codes: "M" denotes conversion/exercise of a derivative (here, RSUs converting to common stock); "F" denotes shares delivered to satisfy tax withholding.